文献速递湿疹皮炎与荨麻疹

婴儿特应性皮炎严重程度的全身与角质层生物标志物包括固有免疫、辅助性T细胞相关免疫及血管生成标志物

Systemic and stratum corneum biomarkers of severity in infant atopic dermatitis include markers of innate and T helper cell-related immunity and angiogenesis.
PubMed 文献 · Br J Dermatol · 2018-10-04

研究招募100例初诊且未接受外用或系统抗炎治疗的特应性皮炎(AD)婴儿与20名健康儿童,比较角质层(SC)与血浆生物标志物及皮肤屏障指标。19种SC和12种血浆标志物在健康与AD皮肤间有显著差异,部分为两腔室共有、部分为腔室特异。AD严重程度相关标志物包括Th2偏向标志物、固有免疫激活标志物、血管生成标志物等。

要点

  • 19种角质层和12种血浆生物标志物在健康与AD皮肤间有显著差异
  • AD严重程度相关标志物包括IL-13、CCL17、CCL22、IL-5等Th2偏向标志物
  • 固有免疫激活标志物(IL-18、IL-1α、IL1β、CXCL8)和血管生成标志物(Flt-1、VEGF)亦与严重程度相关

核心结论

  • 研究识别出具有临床相关性的AD生物标志物,包括可在婴儿中简便采样和检测的新标志物。
  • 这些标志物可能为疾病严重程度提供客观评估,并提示新的治疗靶点或AD疗效测量靶点。
  • 未来研究需确定这些在极早期AD中出现的标志物能否预测疾病结局或合并症。

研究设计与样本

  • 招募100例初诊且未接受外用或系统抗炎治疗的特应性皮炎婴儿和20名健康儿童。
  • 通过胶带剥离角质层(SC)采样临床上未受累皮肤,检测SC和血浆中多种细胞因子、趋化因子及天然保湿因子。
  • 记录疾病严重程度和皮肤屏障功能,比较SC与血浆生物标志物及皮肤屏障结构与功能指标。

主要发现

  • 19种SC和12种血浆生物标志物在健康与AD皮肤间有显著差异。
  • 部分标志物为SC和血浆共有,另一些为腔室特异。
  • AD严重程度相关标志物包括Th2偏向标志物(IL-13、CCL17、CCL22、IL-5)。
  • AD严重程度相关标志物还包括固有免疫激活标志物(IL-18、IL-1α、IL1β、CXCL8)和血管生成标志物(Flt-1、VEGF)。
  • 其他严重程度相关标志物包括可溶性细胞间黏附分子-1、可溶性血管细胞黏附分子-1、IL-16、IL-17A。

局限性

  • 未来研究需确定这些在极早期AD中出现的标志物能否预测疾病结局或合并症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biomarkers of atopic dermatitis (AD) are largely lacking, especially in infant AD. Those that have been examined to date have focused mostly on serum cytokines, with few on noninvasive biomarkers in the skin. OBJECTIVES: We aimed to explore biomarkers obtainable from noninvasive sampling of infant skin. We compared these with plasma biomarkers and structural and functional measures of the skin barrier. METHODS: We recruited 100 infants at first presentation with AD, who were treatment naive to topical or systemic anti-inflammatory therapies, and 20 healthy children. We sampled clinically unaffected skin by tape stripping the stratum corneum (SC). Multiple cytokines and chemokines and natural moisturizing factor were measured in the SC and plasma. We recorded disease severity and skin barrier function. RESULTS: Nineteen SC and 12 plasma biomarkers showed significant differences between healthy and AD skin. Some biomarkers were common to both the SC and plasma, and others were compartment specific. Identified biomarkers of AD severity included T helper 2-skewed markers [interleukin (IL)-13, CCL17, CCL22, IL-5]; markers of innate activation (IL-18, IL-1α, IL1β, CXCL8) and angiogenesis (Flt-1, vascular endothelial growth factor); and others (soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, IL-16, IL-17A). CONCLUSIONS: We identified clinically relevant biomarkers of AD, including novel markers, easily sampled and typed in infants. These markers may provide objective assessment of disease severity and suggest new therapeutic targets, or response measurement targets for AD. Future studies will be required to determine whether these biomarkers, seen in very early AD, can predict disease outcomes or comorbidities.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. McAleer MA, Jakasa I, Hurault G, et al. Systemic and stratum corneum biomarkers of severity in infant atopic dermatitis include markers of innate and T helper cell-related immunity and angiogenesis. Br J Dermatol. 2018. PMID: 30132823. doi:10.1111/bjd.17088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。